

---

**FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY**

---

January 24, 2005

TO: Examiner Maryam Monshipouri  
Group 1652  
571-272-0932

RECEIVED  
CENTRAL FAX CENTER

JAN 24 2005

FROM Justin D. Karjala  
Celera Genomics Corp.  
(240) 453-3812

FAX NO: (703) 872-9306

# OF PAGES (incl. cover): 5

---

Re: U.S. Serial No. 10/820,230, filed April 8, 2004  
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES  
THEREOF"  
Atty. Docket No.: CL001178-DIVIII

A Supplemental Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

---

*The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Chunhua YAN et al.

RECEIVED  
CENTRAL FAX CENTER

JAN 24 2005

Art Unit: 1652

Serial No.: 10/820,230

Examiner: M. Monshipouri

Filed: April 8, 2004

Atty. Docket: CL001178-DIVIII

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

## SUPPLEMENTAL PRELIMINARY AMENDMENT

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231*By Facsimile*

Sir:

This is in response to an Office Action mailed on December 22, 2004 from Examiner Monshipouri in which a further restriction requirement was issued for the above-referenced application.

By way of response, Applicants hereby elect claim group II, claims 3 and 31-43, directed to antibodies, etc., for examination and have canceled claims corresponding to the non-elected group IX.

Please amend the application as follows: